US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
AU770952B2
(en)
|
1999-03-01 |
2004-03-11 |
Genentech Inc. |
Antibodies for cancer therapy and diagnosis
|
EP1591456A1
(en)
*
|
1999-03-01 |
2005-11-02 |
Genentech Inc. |
Antibodies for cancer therapy and diagnosis
|
EP1074563A1
(en)
*
|
1999-08-02 |
2001-02-07 |
F. Hoffmann-La Roche Ag |
Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
|
SE0000597D0
(sv)
*
|
2000-02-24 |
2000-02-24 |
Active Biotech Ab |
Novel antibody
|
AU5720601A
(en)
*
|
2000-04-26 |
2001-11-07 |
Elusys Therapeutics Inc |
Bispecific molecules and uses thereof
|
ES2649037T3
(es)
*
|
2000-12-12 |
2018-01-09 |
Medimmune, Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
RU2316337C2
(ru)
|
2001-04-24 |
2008-02-10 |
Мерк Патент Гмбх |
КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α
|
WO2003087163A1
(fr)
|
2002-04-15 |
2003-10-23 |
Chugai Seiyaku Kabushiki Kaisha |
Procede d'elaboration d'une banque scdb
|
US7732149B2
(en)
|
2002-04-26 |
2010-06-08 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of screening agonistic antibodies
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
AU2013200009B2
(en)
*
|
2002-07-18 |
2015-05-07 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
CA2872136C
(en)
|
2002-07-18 |
2017-06-20 |
Merus B.V. |
Recombinant production of mixtures of antibodies
|
DE602004021095D1
(de)
|
2003-01-21 |
2009-06-25 |
Chugai Pharmaceutical Co Ltd |
Verfahren zum screening der leichten kette eines antikörpers
|
CA2527694C
(en)
|
2003-05-30 |
2015-07-14 |
Hendricus Renerus Jacobus Mattheus Hoogenboom |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
JP4794301B2
(ja)
|
2003-06-11 |
2011-10-19 |
中外製薬株式会社 |
抗体の製造方法
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
EP1693386A4
(en)
*
|
2003-11-04 |
2008-12-31 |
Chugai Pharmaceutical Co Ltd |
METHOD FOR THE PRODUCTION OF ANTIBODIES
|
TW200530269A
(en)
|
2003-12-12 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Anti-Mpl antibodies
|
EP1737971B1
(en)
|
2004-01-20 |
2017-08-16 |
Merus N.V. |
Mixtures of binding proteins
|
EP1765398B1
(en)
*
|
2004-06-01 |
2011-07-13 |
Merck Sharp & Dohme Corp. |
Human antibodies interacting with hiv gp41
|
TWI671403B
(zh)
|
2005-03-31 |
2019-09-11 |
中外製藥股份有限公司 |
控制組裝之多肽的製造方法
|
WO2006106903A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2構造異性体
|
SI1876236T1
(sl)
*
|
2005-04-08 |
2014-11-28 |
Chugai Seiyaku Kabushiki Kaisha |
Protitelo, ki funkcionalno nadomesti faktor viii za koagulacijo krvi
|
AU2006256041B2
(en)
|
2005-06-10 |
2012-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
US9241994B2
(en)
|
2005-06-10 |
2016-01-26 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical compositions containing sc(Fv)2
|
AR056142A1
(es)
|
2005-10-21 |
2007-09-19 |
Amgen Inc |
Metodos para generar el anticuerpo igg monovalente
|
EP1973569B1
(en)
|
2006-01-18 |
2013-05-22 |
Merck Patent GmbH |
Specific therapy using integrin ligands for treating cancer
|
WO2007114325A1
(ja)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
二重特異性抗体を精製するための抗体改変方法
|
US11046784B2
(en)
|
2006-03-31 |
2021-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
WO2007115953A1
(en)
*
|
2006-04-07 |
2007-10-18 |
Novo Nordisk Health Care Ag |
Covalent factor vii-tissue factor complex
|
CA2655362A1
(en)
|
2006-06-13 |
2007-12-21 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
WO2007147901A1
(en)
*
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
ATE555383T1
(de)
|
2006-06-22 |
2012-05-15 |
Novo Nordisk As |
Lösliche heterodimere rezeptoren und ihre verwendung
|
PE20081216A1
(es)
|
2006-09-01 |
2008-09-04 |
Therapeutic Human Polyclonals Inc |
Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos
|
EP3357932A1
(en)
|
2006-09-29 |
2018-08-08 |
OncoMed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
PL2101805T3
(pl)
|
2007-01-18 |
2013-04-30 |
Merck Patent Gmbh |
Ligandy integryn do stosowania w leczeniu nowotworów
|
US8088617B2
(en)
|
2007-01-24 |
2012-01-03 |
Oncomed Pharmaceuticals, Inc. |
Antibodies that bind the glutamate ligand binding region of Notch1
|
AU2008234248C1
(en)
|
2007-03-29 |
2015-01-22 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
PH12018501459A1
(en)
|
2007-09-26 |
2019-11-11 |
Chugai Pharmaceutical Co Ltd |
Modified antibody constant region
|
MX369784B
(es)
|
2007-09-26 |
2019-11-21 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
MX2010004007A
(es)
|
2007-10-15 |
2010-06-15 |
Chugai Pharmaceutical Co Ltd |
Metodo para la produccion de un anticuerpo.
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
WO2009088805A2
(en)
|
2008-01-03 |
2009-07-16 |
The Scripps Research Institute |
Antibody targeting through a modular recognition domain
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
DK2708559T3
(en)
|
2008-04-11 |
2018-06-14 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
|
AU2009263082C1
(en)
|
2008-06-27 |
2018-11-01 |
Merus N.V. |
Antibody producing non-human mammals
|
US9132189B2
(en)
|
2008-07-08 |
2015-09-15 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
PL2307459T3
(pl)
|
2008-07-08 |
2015-05-29 |
Oncomed Pharm Inc |
Czynniki wiążące receptor Notch1 i sposoby ich stosowania
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
WO2010068722A1
(en)
|
2008-12-12 |
2010-06-17 |
Medimmune, Llc |
Crystals and structure of a human igg fc variant with enhanced fcrn binding
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
JP5787446B2
(ja)
|
2009-03-19 |
2015-09-30 |
中外製薬株式会社 |
抗体定常領域改変体
|
BRPI1014089A2
(pt)
|
2009-04-02 |
2016-04-19 |
Roche Glycart Ag |
anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
|
EP2424567B1
(en)
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
WO2010136168A2
(en)
|
2009-05-25 |
2010-12-02 |
Merck Patent Gmbh |
Continuous administration of integrin ligands for treating cancer
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
HUE055817T2
(hu)
|
2009-07-08 |
2021-12-28 |
Kymab Ltd |
Állatmodellek és terápiás molekulák
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
NZ598962A
(en)
|
2009-09-16 |
2014-12-24 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
EP2481752B1
(en)
|
2009-09-24 |
2016-11-09 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
HUE029661T2
(en)
|
2009-10-16 |
2017-03-28 |
Oncomed Pharm Inc |
A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
|
WO2011071577A1
(en)
|
2009-12-11 |
2011-06-16 |
Genentech, Inc. |
Anti-vegf-c antibodies and methods using same
|
PL2516465T3
(pl)
|
2009-12-23 |
2016-11-30 |
|
Przeciwciała anty-bv8 i ich zastosowania
|
MX2012007497A
(es)
|
2009-12-25 |
2012-08-01 |
Chugai Pharmaceutical Co Ltd |
Metodo para modificacion de polipeptidos para purificar multimeros de polipeptido.
|
CN102712769B
(zh)
|
2010-01-29 |
2014-12-03 |
东丽株式会社 |
聚乳酸系树脂片
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
SI3095871T1
(sl)
|
2010-02-08 |
2019-06-28 |
Regeneron Pharmaceuticals, Inc. |
Miš z navadno lahko verigo
|
US20120021409A1
(en)
*
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
JP5889181B2
(ja)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
MX353144B
(es)
|
2010-04-20 |
2017-12-20 |
Genmab As |
Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
|
TWI586806B
(zh)
*
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
異多聚體蛋白質之製造
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
CN103153328A
(zh)
|
2010-07-16 |
2013-06-12 |
默克专利股份有限公司 |
肽在乳腺癌和/或骨转移灶的治疗中的用途
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
JP2013537539A
(ja)
|
2010-08-13 |
2013-10-03 |
ジェネンテック, インコーポレイテッド |
疾患の治療のためのIL−1β及びIL−18に対する抗体
|
ES2537207T3
(es)
|
2010-08-16 |
2015-06-03 |
Novimmune S.A. |
Métodos para la generación de anticuerpos multiespecíficos y multivalentes
|
CA2807278A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann - La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
EP2644698B1
(en)
*
|
2010-11-17 |
2018-01-03 |
Chugai Seiyaku Kabushiki Kaisha |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
RU2663123C2
(ru)
|
2010-11-30 |
2018-08-01 |
Чугаи Сейяку Кабусики Кайся |
Индуцирующий цитотоксичность терапевтический агент
|
CN108715614A
(zh)
|
2010-11-30 |
2018-10-30 |
中外制药株式会社 |
与多分子的抗原重复结合的抗原结合分子
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
EP2670776B1
(en)
*
|
2011-02-04 |
2018-11-21 |
F. Hoffmann-La Roche AG |
Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
MX341921B
(es)
|
2011-02-28 |
2016-09-07 |
Hoffmann La Roche |
Proteinas de union a antigeno.
|
CN103732628B
(zh)
|
2011-03-03 |
2017-06-23 |
酵活有限公司 |
多价杂多聚体骨架设计和构建体
|
EP2683735A1
(en)
|
2011-03-10 |
2014-01-15 |
HCO Antibody, Inc. |
Bispecific three-chain antibody-like molecules
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
EP2686348B1
(en)
|
2011-03-17 |
2015-12-30 |
Ramot at Tel-Aviv University Ltd. |
Bi- and monospecific, asymmetric antibodies and methods of generating the same
|
SG10201602371VA
(en)
|
2011-03-25 |
2016-04-28 |
Glenmark Pharmaceuticals Sa |
Hetero-dimeric immunoglobulins
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
GB201109966D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating pten mutated or deficient cancer
|
GB201109965D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating estrogen receptor alpher(ER) positive cancer
|
JPWO2012176779A1
(ja)
|
2011-06-20 |
2015-02-23 |
協和発酵キリン株式会社 |
抗erbB3抗体
|
US9890218B2
(en)
|
2011-06-30 |
2018-02-13 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
RU2014103185A
(ru)
|
2011-07-18 |
2015-08-27 |
Артс Байолоджикс А/С |
Биологически активное соединение на основе лютеинизирующего гормона (lh) с пролонгированным действием
|
RS61946B1
(sr)
|
2011-08-05 |
2021-07-30 |
Regeneron Pharma |
Humanizovani miševi univerzalnog lakog lakca
|
RU2605390C2
(ru)
|
2011-08-23 |
2016-12-20 |
Рош Гликарт Аг |
Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
|
CA2846319A1
(en)
|
2011-09-19 |
2013-03-28 |
Kymab Limited |
Antibodies, variable domains & chains tailored for human use
|
ES2707580T3
(es)
|
2011-09-23 |
2019-04-04 |
Oncomed Pharm Inc |
Agentes de unión a VEGF/DLL4 y usos de los mismos
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
CN104093744A
(zh)
|
2011-10-11 |
2014-10-08 |
弗·哈夫曼-拉罗切有限公司 |
双特异性抗体的改进的组装
|
AU2012328880B2
(en)
|
2011-10-24 |
2017-02-23 |
Halozyme, Inc. |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
AU2012328322A1
(en)
|
2011-10-27 |
2014-06-12 |
Genmab A/S |
Production of heterodimeric proteins
|
CA2853230C
(en)
|
2011-10-31 |
2021-11-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
EP2794905B1
(en)
|
2011-12-20 |
2020-04-01 |
MedImmune, LLC |
Modified polypeptides for bispecific antibody scaffolds
|
BR112014013035A2
(pt)
*
|
2011-12-22 |
2018-10-09 |
Hoffmann La Roche |
métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
|
WO2013119966A2
(en)
*
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
US9301510B2
(en)
|
2012-03-16 |
2016-04-05 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with pH-dependent binding characteristics
|
EP2883449B1
(en)
|
2012-03-16 |
2018-02-07 |
Regeneron Pharmaceuticals, Inc. |
Histidine engineered light chain antibodies and genetically modified rodents for generating the same
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
BR112014022855A2
(pt)
|
2012-03-16 |
2017-07-18 |
Regeneron Pharma |
animal não humano geneticamente modificado, mamífero geneticamente modificado, e, método para fabricar um animal não humano
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
AU2013244999A1
(en)
|
2012-04-05 |
2014-09-25 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against human TWEAK and human IL17 and uses thereof
|
ES2743399T3
(es)
|
2012-04-20 |
2020-02-19 |
Merus Nv |
Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
|
CN104583239B
(zh)
*
|
2012-05-10 |
2018-09-18 |
生物蛋白有限公司 |
多特异单克隆抗体
|
JP6628966B2
(ja)
|
2012-06-14 |
2020-01-15 |
中外製薬株式会社 |
改変されたFc領域を含む抗原結合分子
|
BR112014028368A2
(pt)
|
2012-06-27 |
2017-11-14 |
Hoffmann La Roche |
método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
|
EP2867253B1
(en)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
CN104394886B
(zh)
|
2012-07-04 |
2017-05-24 |
弗·哈夫曼-拉罗切有限公司 |
抗茶碱抗体及使用方法
|
EP2869848B1
(en)
|
2012-07-04 |
2016-09-21 |
F. Hoffmann-La Roche AG |
Covalently linked antigen-antibody conjugates
|
EP3339328A1
(en)
|
2012-07-04 |
2018-06-27 |
F. Hoffmann-La Roche AG |
Anti-biotin antibodies and methods of use
|
CN104736174B
(zh)
|
2012-07-06 |
2019-06-14 |
根马布私人有限公司 |
具有三重突变的二聚体蛋白质
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
JP6498601B2
(ja)
*
|
2012-07-13 |
2019-04-10 |
ザイムワークス,インコーポレイテッド |
多価ヘテロ多量体足場設計および構築物
|
CA2882272C
(en)
|
2012-08-24 |
2023-08-29 |
Chugai Seiyaku Kabushiki Kaisha |
Fc.gamma.riib-specific fc region variant
|
EP3470431A1
(en)
*
|
2012-09-27 |
2019-04-17 |
Merus N.V. |
Bispecific igg antibodies as t cell engagers
|
BR112015007120A2
(pt)
|
2012-10-08 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
WO2014071018A1
(en)
|
2012-10-31 |
2014-05-08 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a dll4 antagonist
|
KR102152481B1
(ko)
|
2012-11-05 |
2020-09-04 |
젠야쿠코교가부시키가이샤 |
항체 또는 항체 조성물의 제조 방법
|
EP3489258A1
(en)
|
2012-11-08 |
2019-05-29 |
Eleven Biotherapeutics, Inc. |
Il-6 antagonists and uses thereof
|
ES2876009T3
(es)
|
2012-12-27 |
2021-11-11 |
Chugai Pharmaceutical Co Ltd |
Polipéptido heterodimerizado
|
KR20160007478A
(ko)
|
2013-01-10 |
2016-01-20 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
EP2943511B1
(en)
|
2013-01-14 |
2019-08-07 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
EP2945969A1
(en)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
RU2015140915A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
KR101833602B1
(ko)
|
2013-02-26 |
2018-02-28 |
로슈 글리카트 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
MX2015012709A
(es)
*
|
2013-03-14 |
2016-05-31 |
Macrogenics Inc |
Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas.
|
WO2014145907A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Targeting t cells with heterodimeric proteins
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
WO2014144600A2
(en)
|
2013-03-15 |
2014-09-18 |
Viktor Roschke |
Multivalent and monovalent multispecific complexes and their uses
|
EP2992010B1
(en)
|
2013-04-29 |
2021-03-24 |
F.Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
EP3327034A1
(en)
|
2013-04-29 |
2018-05-30 |
F. Hoffmann-La Roche AG |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
MY172430A
(en)
|
2013-04-29 |
2019-11-25 |
Hoffmann La Roche |
Human fcrn-binding modified antibodies and methods of use
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
SG10201800982QA
(en)
|
2013-07-05 |
2018-03-28 |
Genmab As |
Humanized or chimeric cd3 antibodies
|
EA035319B1
(ru)
*
|
2013-07-31 |
2020-05-27 |
Эмджен Инк. |
СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ
|
RU2758952C1
(ru)
|
2013-09-27 |
2021-11-03 |
Чугаи Сейяку Кабусики Кайся |
Способ получения полипептидного гетеромультимера
|
MX2016003617A
(es)
|
2013-09-30 |
2016-07-21 |
Chugai Pharmaceutical Co Ltd |
Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
|
TW201546284A
(zh)
|
2013-10-01 |
2015-12-16 |
Kymab Ltd |
動物模式及治療分子
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
CA2929044A1
(en)
|
2013-11-11 |
2015-05-14 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified antibody variable region
|
CN110156893B
(zh)
|
2013-12-17 |
2023-03-03 |
基因泰克公司 |
抗cd3抗体及使用方法
|
CN105899533B
(zh)
|
2013-12-20 |
2019-10-11 |
豪夫迈·罗氏有限公司 |
人源化的抗-Tau(pS422)抗体和使用方法
|
RU2016129517A
(ru)
*
|
2013-12-20 |
2018-01-25 |
Ф. Хоффманн-Ля Рош Аг |
Биспецифические антитела к her2 и способы применения
|
JP6476194B2
(ja)
|
2014-01-03 |
2019-02-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
二重特異性抗ハプテン/抗血液脳関門受容体抗体、それらの複合体、及び血液脳関門シャトルとしてのそれらの使用
|
MX2016008191A
(es)
|
2014-01-03 |
2017-11-16 |
Hoffmann La Roche |
Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
|
BR112016012666A2
(pt)
|
2014-01-03 |
2017-09-26 |
Hoffmann La Roche |
conjugado, anticorpos, formulação farmacêutica e usos de conjugado
|
RU2694659C2
(ru)
|
2014-01-06 |
2019-07-16 |
Ф. Хоффманн-Ля Рош Аг |
Одновалентные модули-переносчики через гематоэнцефалический барьер
|
EP3835318A1
(en)
|
2014-01-15 |
2021-06-16 |
F. Hoffmann-La Roche AG |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
KR20160124165A
(ko)
|
2014-02-21 |
2016-10-26 |
제넨테크, 인크. |
항-il-13/il-17 이중특이적 항체 및 그의 용도
|
US11279770B2
(en)
|
2014-02-28 |
2022-03-22 |
Merus N.V. |
Antibody that binds ErbB-2 and ErbB-3
|
WO2015130172A1
(en)
|
2014-02-28 |
2015-09-03 |
Merus B.V. |
Antibodies that bind egfr and erbb3
|
US10435694B2
(en)
|
2014-03-14 |
2019-10-08 |
Genentech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US10881085B2
(en)
|
2014-03-21 |
2021-01-05 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
SG10202008629XA
(en)
|
2014-03-28 |
2020-10-29 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3
|
EP3126384B1
(en)
*
|
2014-04-01 |
2020-12-02 |
Adimab, LLC |
Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
|
SG11201608054YA
(en)
|
2014-04-02 |
2016-10-28 |
Hoffmann La Roche |
Method for detecting multispecific antibody light chain mispairing
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
NZ724710A
(en)
|
2014-04-07 |
2024-02-23 |
Chugai Pharmaceutical Co Ltd |
Immunoactivating antigen-binding molecule
|
BR112016024462B1
(pt)
|
2014-05-06 |
2022-12-27 |
Genentech, Inc |
Métodos para a preparação de um anticorpo
|
WO2015175639A1
(en)
|
2014-05-13 |
2015-11-19 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising aav expressing dual antibody constructs and uses thereof
|
BR112016026299A2
(pt)
|
2014-05-13 |
2018-02-20 |
Chugai Seiyaku Kabushiki Kaisha |
molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão
|
EP3164419A1
(en)
|
2014-06-26 |
2017-05-10 |
F. Hoffmann-La Roche AG |
Anti-brdu antibodies and methods of use
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
AU2015286569B2
(en)
|
2014-07-11 |
2021-04-15 |
Genmab A/S |
Antibodies binding AXL
|
MA40510A
(fr)
|
2014-08-04 |
2017-06-14 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
EP3191520B1
(en)
|
2014-09-12 |
2020-01-01 |
Genentech, Inc. |
Anti-cll-1 antibodies and immunoconjugates
|
SG10201809668TA
(en)
|
2014-09-12 |
2018-11-29 |
Genentech Inc |
Anti-her2 antibodies and immunoconjugates
|
US10077318B2
(en)
|
2014-09-12 |
2018-09-18 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
CN107124870A
(zh)
|
2014-09-17 |
2017-09-01 |
基因泰克公司 |
包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
TWI701435B
(zh)
|
2014-09-26 |
2020-08-11 |
日商中外製藥股份有限公司 |
測定fviii的反應性之方法
|
TWI700300B
(zh)
|
2014-09-26 |
2020-08-01 |
日商中外製藥股份有限公司 |
中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
|
JP6708635B2
(ja)
|
2014-10-09 |
2020-06-10 |
エンクマフ エスアーエールエル |
CD3εおよびROR1に対する二特異性抗体
|
EA201700181A1
(ru)
|
2014-10-14 |
2017-09-29 |
Галозим, Инк. |
Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
|
JP6827415B2
(ja)
|
2014-10-31 |
2021-02-10 |
メレオ バイオファーマ 5 インコーポレイテッド |
疾患の処置のための併用療法
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
BR112017006591A2
(pt)
|
2014-11-06 |
2018-01-16 |
Hoffmann La Roche |
polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
|
WO2016071376A2
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
SG11201703574VA
(en)
|
2014-11-07 |
2017-05-30 |
Eleven Biotherapeutics Inc |
Improved il-6 antibodies
|
EA201791029A1
(ru)
|
2014-11-10 |
2017-12-29 |
Дженентек, Инк. |
Антитела против интерлейкина-33 и их применение
|
CN107250158B
(zh)
|
2014-11-19 |
2022-03-25 |
基因泰克公司 |
抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
|
KR20170087486A
(ko)
*
|
2014-11-20 |
2017-07-28 |
에프. 호프만-라 로슈 아게 |
일반 경쇄 및 이의 사용 방법
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
ES2835823T3
(es)
|
2014-11-20 |
2021-06-23 |
Hoffmann La Roche |
Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1
|
IL252480B2
(en)
|
2014-11-26 |
2023-12-01 |
Xencor Inc |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
JP2017536830A
(ja)
|
2014-11-26 |
2017-12-14 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Cd3及びcd38に結合するヘテロ二量体抗体
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
WO2016094566A2
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
US10865253B2
(en)
|
2014-12-19 |
2020-12-15 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
EP3271403A1
(en)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
JP2018516933A
(ja)
|
2015-06-02 |
2018-06-28 |
ジェネンテック, インコーポレイテッド |
抗il−34抗体を使用して神経学的疾患を治療するための組成物及び方法
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
AR105026A1
(es)
|
2015-06-16 |
2017-08-30 |
Genentech Inc |
ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
|
WO2016207245A1
(en)
|
2015-06-24 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Humanized anti-tau(ps422) antibodies and methods of use
|
WO2016207091A1
(en)
*
|
2015-06-24 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
|
EP3319993B1
(en)
|
2015-07-10 |
2020-01-15 |
Genmab A/S |
Axl-specific antibody-drug conjugates for cancer treatment
|
DK3115376T3
(en)
|
2015-07-10 |
2018-11-26 |
Merus Nv |
HUMANT CD3 BINDING ANTIBODY
|
IL256562B1
(en)
|
2015-07-15 |
2024-03-01 |
Genmab As |
Human CD3 antibodies or chimeras
|
EP3353204B1
(en)
|
2015-09-23 |
2023-10-18 |
Mereo BioPharma 5, Inc. |
Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
CN108026179A
(zh)
|
2015-10-02 |
2018-05-11 |
豪夫迈·罗氏有限公司 |
结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
BR112018000835A2
(pt)
|
2015-10-02 |
2018-09-11 |
Hoffmann La Roche |
molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
WO2017055404A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for pd1 and tim3
|
EP3356407B1
(en)
|
2015-10-02 |
2021-11-03 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
US20170096495A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
CN108139394B
(zh)
|
2015-10-02 |
2020-10-30 |
豪夫迈·罗氏有限公司 |
用于确定同时结合的基于细胞的fret测定法
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
CN108136010A
(zh)
|
2015-10-08 |
2018-06-08 |
宏观基因有限公司 |
用于治疗癌症的联合疗法
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
CN108602888B
(zh)
|
2015-10-23 |
2022-10-04 |
美勒斯公司 |
抑制癌症生长的结合分子
|
SG11201802698XA
(en)
*
|
2015-10-29 |
2018-05-30 |
Hoffmann La Roche |
Transgenic rabbit with common light chain
|
KR20180069065A
(ko)
|
2015-10-29 |
2018-06-22 |
에프. 호프만-라 로슈 아게 |
항-변이체 fc-부위 항체 및 사용 방법
|
CN108289951A
(zh)
|
2015-10-30 |
2018-07-17 |
豪夫迈·罗氏有限公司 |
抗-因子d抗体和缀合物
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
US11623957B2
(en)
|
2015-12-07 |
2023-04-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
PL3387015T3
(pl)
|
2015-12-09 |
2022-02-14 |
F. Hoffmann-La Roche Ag |
Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
KR20180091918A
(ko)
|
2015-12-28 |
2018-08-16 |
추가이 세이야쿠 가부시키가이샤 |
Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법
|
KR20180098625A
(ko)
|
2015-12-30 |
2018-09-04 |
제넨테크, 인크. |
분해가 감소된 폴리소르베이트를 갖는 제형
|
AU2016381694A1
(en)
|
2015-12-30 |
2018-07-05 |
Genentech, Inc. |
Use of tryptophan derivatives for protein formulations
|
CA3006529A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
CA3016424A1
(en)
|
2016-03-14 |
2017-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
PE20231511A1
(es)
|
2016-03-22 |
2023-09-26 |
Hoffmann La Roche |
Moleculas biespecificas de celulas t activadas por proteasas que se unen especificamente al receptor 1 de folato (folr1) y cd3
|
WO2017181152A2
(en)
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
SG11201808457PA
(en)
|
2016-04-15 |
2018-10-30 |
Alpine Immune Sciences Inc |
Icos ligand variant immunomodulatory proteins and uses thereof
|
UA123323C2
(uk)
|
2016-05-02 |
2021-03-17 |
Ф. Хоффманн-Ля Рош Аг |
Димерний злитий поліпептид
|
JP2019522633A
(ja)
|
2016-05-20 |
2019-08-15 |
ジェネンテック, インコーポレイテッド |
Protac抗体コンジュゲート及び使用方法
|
US20170370906A1
(en)
|
2016-05-27 |
2017-12-28 |
Genentech, Inc. |
Bioanalytical analysis of site-specific antibody drug conjugates
|
BR112019022558A2
(pt)
|
2016-06-02 |
2020-05-19 |
Hoffmann La Roche |
anticorpos, métodos para tratar ou retardar a progressão de uma doença proliferativa e para tratar ou retardar a progressão do câncer em um indivíduo, composições farmacêuticas, kit, usos de uma combinação de um anticorpo anti-cd20 e de um anticorpo e invenção
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
EP3464280B1
(en)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol antibody-drug conjugates and methods of use
|
IL263542B1
(en)
|
2016-06-14 |
2024-06-01 |
Xencor Inc |
Bispecific antibodies inhibit immunological checkpoint
|
AR108800A1
(es)
|
2016-06-17 |
2018-09-26 |
Genentech Inc |
Purificación de anticuerpos multiespecíficos
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
JP7308034B2
(ja)
|
2016-07-01 |
2023-07-13 |
リゾルブ セラピューティクス, エルエルシー |
最適化二重ヌクレアーゼ融合物および方法
|
CN109415435B
(zh)
|
2016-07-04 |
2024-01-16 |
豪夫迈·罗氏有限公司 |
新型抗体形式
|
BR112019000512A2
(pt)
|
2016-07-14 |
2019-04-24 |
Genmab A/S |
anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
EP3496763A1
(en)
|
2016-08-11 |
2019-06-19 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
MX2019002510A
(es)
|
2016-09-06 |
2019-06-24 |
Chugai Pharmaceutical Co Ltd |
Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado.
|
DK4050034T3
(da)
|
2016-09-14 |
2024-06-03 |
Teneoone Inc |
Cd3-bindende antistoffer
|
CN109791149A
(zh)
|
2016-09-30 |
2019-05-21 |
豪夫迈·罗氏有限公司 |
用于功能分析多特异性分子的基于spr的双重结合测定法
|
ES2897217T3
(es)
|
2016-09-30 |
2022-02-28 |
Hoffmann La Roche |
Anticuerpos biespecíficos frente a p95HER2
|
EP3522933B1
(en)
|
2016-10-05 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Methods for preparing antibody drug conjugates
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
AU2017342559B2
(en)
|
2016-10-14 |
2022-03-24 |
Xencor, Inc. |
Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments
|
CN110461868A
(zh)
|
2016-11-01 |
2019-11-15 |
根马布私人有限公司 |
多肽变体及其用途
|
TWI791471B
(zh)
|
2016-11-15 |
2023-02-11 |
美商建南德克公司 |
用於用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
CA3045323A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
IL300729A
(en)
|
2016-12-21 |
2023-04-01 |
Teneobio Inc |
Anti-BCMA antibodies containing only heavy chains
|
MX2019009346A
(es)
|
2017-02-10 |
2019-10-02 |
Genmab Bv |
Variantes de polipeptidos y usos de los mismos.
|
EP3592769B1
(en)
|
2017-03-09 |
2024-05-08 |
Genmab A/S |
Antibodies against pd-l1
|
JP7021245B2
(ja)
|
2017-03-10 |
2022-02-16 |
エフ.ホフマン-ラ ロシュ アーゲー |
多重特異性抗体を生産するための方法
|
AU2018235838B2
(en)
|
2017-03-16 |
2023-12-14 |
Alpine Immune Sciences, Inc. |
CD80 variant immunomodulatory proteins and uses thereof
|
KR20240039221A
(ko)
|
2017-03-16 |
2024-03-26 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l1 리간드 변이체 면역조절 단백질 및 그의 용도
|
AU2018235835A1
(en)
|
2017-03-16 |
2019-09-05 |
Alpine Immune Sciences, Inc. |
PD-L2 variant immunomodulatory proteins and uses thereof
|
JP7050333B2
(ja)
|
2017-03-24 |
2022-04-08 |
全薬工業株式会社 |
抗IgM/B細胞表面抗原二重特異性抗体
|
CA3057907A1
(en)
|
2017-03-31 |
2018-10-04 |
Genmab Holding B.V. |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
AU2018246873B2
(en)
|
2017-03-31 |
2021-05-06 |
Merus N.V. |
ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
|
UA125700C2
(uk)
|
2017-04-03 |
2022-05-18 |
Ф. Хоффманн-Ля Рош Аг |
Імунокон'югати антитіла до pd-1 з мутантом il-2
|
EP3606947B1
(en)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
CA3055132A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Antibodies binding to steap-1
|
SG11201909154SA
(en)
|
2017-04-05 |
2019-10-30 |
Hoffmann La Roche |
Bispecific antibodies specifically binding to pd1 and lag3
|
EP3606954B1
(en)
|
2017-04-05 |
2022-07-20 |
F. Hoffmann-La Roche AG |
Anti-lag3 antibodies
|
CA3058477A1
(en)
|
2017-04-11 |
2018-10-18 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
EP3630836A1
(en)
*
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
CN111328335A
(zh)
|
2017-06-07 |
2020-06-23 |
根马布私人有限公司 |
基于突变igg六聚体的治疗性抗体
|
IL271194B1
(en)
|
2017-06-20 |
2024-06-01 |
Teneobio Inc |
Anti-BCMA antibodies containing only heavy chains
|
BR112019026803A2
(pt)
|
2017-06-20 |
2020-06-30 |
Teneoone, Inc. |
anticorpos apenas de cadeia pesada anti-bcma
|
GB201709970D0
(en)
|
2017-06-22 |
2017-08-09 |
Kymab Ltd |
Bispecific antigen-binding molecules
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
CA3068929A1
(en)
|
2017-07-06 |
2019-01-10 |
Merus N.V. |
Binding molecules that modulate a biological activity expressed by a cell
|
GB201710984D0
(en)
|
2017-07-07 |
2017-08-23 |
Kymab Ltd |
Cells, vertebrates, populations & methods
|
AR112603A1
(es)
|
2017-07-10 |
2019-11-20 |
Lilly Co Eli |
Anticuerpos biespecíficos inhibidores de punto de control
|
EP3428194B1
(en)
|
2017-07-14 |
2021-08-18 |
Immatics Biotechnologies GmbH |
Improved dual specificity polypeptide molecule
|
DE102017115966A1
(de)
|
2017-07-14 |
2019-01-17 |
Immatics Biotechnologies Gmbh |
Polypeptidmolekül mit verbesserter zweifacher Spezifität
|
SG11202000198QA
(en)
|
2017-08-04 |
2020-02-27 |
Genmab As |
Binding agents binding to pd-l1 and cd137 and use thereof
|
SG11202001050PA
(en)
|
2017-08-09 |
2020-03-30 |
Merus Nv |
Antibodies that bind egfr and cmet
|
CN111315767A
(zh)
|
2017-08-22 |
2020-06-19 |
萨纳生物有限责任公司 |
可溶性干扰素受体及其用途
|
EP3457139A1
(en)
|
2017-09-19 |
2019-03-20 |
Promise Advanced Proteomics |
Antibody-like peptides for quantifying therapeutic antibodies
|
CA3071236A1
(en)
|
2017-09-29 |
2019-04-04 |
Chugai Seiyaku Kabushiki Kaisha |
Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
|
CA3077509A1
(en)
|
2017-10-10 |
2019-04-18 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
US20200283500A1
(en)
|
2017-10-18 |
2020-09-10 |
Alpine Immune Sciences, Inc. |
Variant icos ligand immunomodulatory proteins and related compositions and methods
|
EP3697441B1
(en)
|
2017-10-20 |
2023-06-07 |
F. Hoffmann-La Roche AG |
Method for generating multispecific antibodies from monospecific antibodies
|
BR112020007736A2
(pt)
|
2017-10-30 |
2020-10-20 |
F. Hoffmann-La Roche Ag |
composição e método de tratamento
|
WO2019089544A1
(en)
|
2017-11-01 |
2019-05-09 |
Tufts Medical Center, Inc. |
Bispecific antibody constructs and methods of use
|
KR102559706B1
(ko)
|
2017-11-01 |
2023-07-25 |
에프. 호프만-라 로슈 아게 |
Trifab-콘톨스바디
|
US20210324108A1
(en)
|
2017-11-01 |
2021-10-21 |
Hoffmann-La Roche Inc. |
Bispecific 2+1 contorsbodies
|
WO2019086394A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
The compbody - a multivalent target binder
|
EP3703746A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Novel tnf family ligand trimer-containing antigen binding molecules
|
JP7311425B2
(ja)
|
2017-11-08 |
2023-07-19 |
協和キリン株式会社 |
CD40とEpCAMに結合するバイスペシフィック抗体
|
CA3082383A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US11773171B2
(en)
|
2017-12-19 |
2023-10-03 |
Surrozen Operating, Inc. |
WNT surrogate molecules and uses thereof
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
JP7418332B2
(ja)
|
2017-12-19 |
2024-01-19 |
スロゼン オペレーティング, インコーポレイテッド |
抗フリズルド抗体及び使用方法
|
AU2018393076A1
(en)
|
2017-12-19 |
2020-07-02 |
Surrozen Operating, Inc. |
Anti-LRP5/6 antibodies and methods of use
|
PE20201149A1
(es)
|
2017-12-21 |
2020-10-26 |
Hoffmann La Roche |
Anticuerpos de union a hla-a2/wt1
|
CN111491951B
(zh)
|
2017-12-22 |
2024-05-24 |
豪夫迈·罗氏有限公司 |
通过疏水相互作用色谱法耗尽轻链错配的抗体变体
|
SG11202006042SA
(en)
|
2017-12-27 |
2020-07-29 |
Teneobio Inc |
Cd3-delta/epsilon heterodimer specific antibodies
|
CA3082280A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against tigit
|
JP7314146B2
(ja)
|
2017-12-28 |
2023-07-25 |
中外製薬株式会社 |
細胞傷害誘導治療剤
|
CN111511400A
(zh)
|
2017-12-29 |
2020-08-07 |
豪夫迈·罗氏有限公司 |
抗vegf抗体及其使用方法
|
EP3735417A1
(en)
|
2018-01-03 |
2020-11-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
TWI802633B
(zh)
|
2018-01-15 |
2023-05-21 |
大陸商南京傳奇生物科技有限公司 |
針對pd-1之單域抗體及其變異體
|
JP2021510740A
(ja)
|
2018-01-24 |
2021-04-30 |
ゲンマブ ビー.ブイ. |
ポリペプチド変種およびそれらの用途
|
EP3746480A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
EP3746470A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Stabilized immunoglobulin domains
|
CN111699004A
(zh)
|
2018-02-06 |
2020-09-22 |
豪夫迈·罗氏有限公司 |
眼科疾病的治疗
|
AR115360A1
(es)
|
2018-02-08 |
2021-01-13 |
Genentech Inc |
Moléculas de unión al antígeno y métodos de uso
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
CN113166220A
(zh)
|
2018-03-09 |
2021-07-23 |
奥美药业有限公司 |
创新细胞因子前药
|
BR112020018490A2
(pt)
|
2018-03-12 |
2020-12-29 |
Genmab A/S |
Anticorpo, imunoconjugado ou conjugado de anticorpo-fármaco, construção de ácido nucléico, vetor de expressão, célula, composição, composição farmacêutica, anticorpo, método, método para produzir um anticorpo, kit de partes, e, anticorpo anti-idiotípico
|
MX2020010028A
(es)
|
2018-03-29 |
2020-10-14 |
Genentech Inc |
Actividad lactogenica modulada en celulas de mamifero.
|
EP3774917A4
(en)
|
2018-03-30 |
2022-01-19 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AGAINST LAG-3 AND USES THEREOF
|
AU2019243665B2
(en)
|
2018-03-30 |
2023-06-01 |
Merus N.V. |
Multivalent antibody
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
BR112020020604A2
(pt)
|
2018-04-11 |
2021-01-12 |
Inhibrx, Inc. |
Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
|
US11505595B2
(en)
|
2018-04-18 |
2022-11-22 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
JP2021521784A
(ja)
|
2018-04-18 |
2021-08-30 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RaFc融合タンパク質とPD−1抗原結合ドメインを含むPD−1標的化ヘテロダイマー融合タンパク質およびそれらの使用
|
CA3098486A1
(en)
|
2018-05-03 |
2019-11-07 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
GB201808927D0
(en)
|
2018-05-31 |
2018-07-18 |
Institute Of Cancer Res Royal Cancer Hospital |
Materials and methods for monitoring the development of resistance of cancers to treatment
|
TW202016151A
(zh)
|
2018-06-09 |
2020-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
US20210363219A1
(en)
|
2018-06-15 |
2021-11-25 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
WO2019244973A1
(ja)
|
2018-06-20 |
2019-12-26 |
中外製薬株式会社 |
標的細胞に対する免疫反応を活性化する方法およびその組成物
|
WO2019243636A1
(en)
|
2018-06-22 |
2019-12-26 |
Genmab Holding B.V. |
Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
|
JP2021526845A
(ja)
|
2018-07-13 |
2021-10-11 |
ゲンマブ エー/エス |
Cd38抗体を使用したトロゴサイトーシスを介した治療
|
PE20211858A1
(es)
|
2018-07-13 |
2021-09-21 |
Genmab As |
Variantes de anticuerpos anti-cd38 y sus usos
|
TW202035451A
(zh)
|
2018-07-24 |
2020-10-01 |
美商英伊布里克斯公司 |
含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
|
US20210163562A1
(en)
|
2018-07-25 |
2021-06-03 |
AskGene Pharma, Inc. |
Novel IL-21 Prodrugs and Methods of Use Thereof
|
US11220554B2
(en)
|
2018-09-07 |
2022-01-11 |
Novo Nordisk A/S |
Procoagulant antibodies
|
CN117343188A
(zh)
*
|
2018-08-01 |
2024-01-05 |
诺和诺德股份有限公司 |
改进的促凝血抗体
|
WO2020033485A1
(en)
|
2018-08-08 |
2020-02-13 |
Genentech, Inc. |
Use of tryptophan derivatives and l-methionine for protein formulation
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
AU2019340647A1
(en)
|
2018-09-10 |
2021-03-11 |
Genentech, Inc. |
Systems and methods for affinity capillary electrophoresis
|
US20220177587A1
(en)
|
2018-09-19 |
2022-06-09 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant cd80 fusion proteins and related constructs
|
WO2020072821A2
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
KR20210116429A
(ko)
|
2018-10-04 |
2021-09-27 |
젠맵 홀딩 비.브이. |
이중특이적 항-cd37 항체를 포함하는 제약 조성물
|
CN113166261A
(zh)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
B7h3单域抗体及其治疗性组合物
|
JP7453219B2
(ja)
|
2018-10-11 |
2024-03-19 |
インヒブリックス, インコーポレイテッド |
Pd-1単一ドメイン抗体およびその治療用組成物
|
TW202021986A
(zh)
|
2018-10-11 |
2020-06-16 |
美商英伊布里克斯公司 |
5t4單域抗體及其治療性組合物
|
CA3115089A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
JP2022505450A
(ja)
|
2018-10-24 |
2022-01-14 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
コンジュゲート化された化学的分解誘導物質および使用方法
|
BR112021007946A2
(pt)
|
2018-10-29 |
2021-08-03 |
F. Hoffmann-La Roche Ag |
formulação de anticorpo
|
WO2020089437A1
(en)
|
2018-10-31 |
2020-05-07 |
Engmab Sàrl |
Combination therapy
|
JP2022512875A
(ja)
|
2018-11-06 |
2022-02-07 |
ゲンマブ エー/エス |
抗体製剤
|
KR20210135987A
(ko)
|
2018-11-30 |
2021-11-16 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Cd86 변이체 면역조절 단백질 및 그의 용도
|
CA3121699A1
(en)
|
2018-12-05 |
2020-06-11 |
Morphosys Ag |
Multispecific antigen-binding molecules
|
WO2020123275A1
(en)
|
2018-12-10 |
2020-06-18 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
GB201820687D0
(en)
|
2018-12-19 |
2019-01-30 |
Kymab Ltd |
Antagonists
|
JP2022515770A
(ja)
|
2018-12-21 |
2022-02-22 |
カイマブ・リミテッド |
共通の軽鎖を有するFIXa×FX二重特異性抗体
|
SG10202105788SA
(en)
|
2018-12-21 |
2021-06-29 |
Hoffmann La Roche |
Antibodies binding to cd3
|
JP2022515473A
(ja)
|
2018-12-28 |
2022-02-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
免疫応答が増幅された患者における治療的使用のためのペプチド-mhc-i-抗体融合タンパク質
|
MX2021007797A
(es)
|
2018-12-28 |
2021-10-26 |
Kyowa Kirin Co Ltd |
Anticuerpo biespecifico que se une al receptor de transferrina (tfr).
|
CN113439089A
(zh)
*
|
2018-12-31 |
2021-09-24 |
美勒斯公司 |
截短的多价多元体
|
EP3906062A1
(en)
|
2019-01-04 |
2021-11-10 |
Resolve Therapeutics, LLC |
Treatment of sjogren's disease with nuclease fusion proteins
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
SG11202109406TA
(en)
|
2019-03-01 |
2021-09-29 |
Xencor Inc |
Heterodimeric antibodies that bind enpp3 and cd3
|
JP7412440B2
(ja)
|
2019-03-29 |
2024-01-12 |
エフ. ホフマン-ラ ロシュ アーゲー |
アビド結合多重特異性抗体を作製する方法
|
EP3948281A1
(en)
|
2019-03-29 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Spr-based binding assay for the functional analysis of multivalent molecules
|
KR102652906B1
(ko)
|
2019-04-17 |
2024-04-01 |
노보 노르디스크 에이/에스 |
이중 특이적 항체
|
CA3136816A1
(en)
|
2019-04-17 |
2020-10-22 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant icos ligand (icosl) fusion proteins
|
EP3959238A1
(en)
|
2019-04-25 |
2022-03-02 |
F. Hoffmann-La Roche AG |
Activatable therapeutic multispecific polypeptides with extended half-life
|
BR112021020843A2
(pt)
|
2019-04-25 |
2022-02-01 |
Hoffmann La Roche |
Conjunto de polipeptídeos precursores heterodiméricos, polipeptídeos heterodiméricos, métodos para gerar um polipeptídeo heterodimérico e para identificar um polipeptídeo heterodimérico multiespecífico, polipeptídeo heterodimérico multiespecífico, primeiro e segundo polipeptídeo precursor heterodimérico
|
WO2020216879A1
(en)
|
2019-04-25 |
2020-10-29 |
F. Hoffmann-La Roche Ag |
Therapeutic multispecific polypeptides activated by polypeptide chain exchange
|
JP2022531894A
(ja)
|
2019-05-09 |
2022-07-12 |
ゲンマブ ビー.ブイ. |
がんの処置において使用するための抗dr5抗体の組み合わせの投与レジメン
|
EP3969907A1
(en)
|
2019-05-13 |
2022-03-23 |
F. Hoffmann-La Roche AG |
Interference-suppressed pharmacokinetic immunoassay
|
WO2020230899A1
(ja)
|
2019-05-15 |
2020-11-19 |
協和キリン株式会社 |
Cd40とfapに結合するバイスペシフィック抗体
|
TW202108625A
(zh)
|
2019-05-15 |
2021-03-01 |
日商協和麒麟股份有限公司 |
與cd40及gpc3結合之雙專一性抗體
|
AU2020288499A1
(en)
|
2019-06-05 |
2022-01-27 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody cleavage site-binding molecule
|
JP2022536898A
(ja)
|
2019-06-12 |
2022-08-22 |
アスクジーン・ファーマ・インコーポレイテッド |
新規il-15プロドラッグおよびその使用方法
|
TW202108628A
(zh)
|
2019-06-14 |
2021-03-01 |
美商泰尼歐生物公司 |
與c d 2 2 及c d 3 結合之多特異性重鏈抗體
|
BR112021025425A2
(pt)
|
2019-06-19 |
2022-02-01 |
Hoffmann La Roche |
Método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre
|
KR20220016957A
(ko)
|
2019-06-26 |
2022-02-10 |
에프. 호프만-라 로슈 아게 |
Sirt-1 유전자 녹아웃을 갖는 포유류 세포주
|
CN114051500A
(zh)
|
2019-07-02 |
2022-02-15 |
豪夫迈·罗氏有限公司 |
包含白细胞介素-2突变体和抗cd8抗体的免疫缀合物
|
TW202116805A
(zh)
|
2019-07-10 |
2021-05-01 |
日商中外製藥股份有限公司 |
Claudin-6結合分子以及其用途
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
JP2022541459A
(ja)
|
2019-07-16 |
2022-09-26 |
サノフイ |
アルツハイマー病の処置のための中和抗アミロイドベータ抗体
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
BR112022001460A2
(pt)
|
2019-07-31 |
2022-03-22 |
Hoffmann La Roche |
Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
|
WO2021030483A1
(en)
|
2019-08-12 |
2021-02-18 |
AskGene Pharma, Inc. |
Il-2 fusion proteins that preferentially bind il-2ralpha
|
JP2022545439A
(ja)
|
2019-08-21 |
2022-10-27 |
アスクジーン・ファーマ・インコーポレイテッド |
新規il-21プロドラッグおよびその使用方法
|
CA3150999A1
(en)
|
2019-09-18 |
2021-03-25 |
James Thomas Koerber |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
AU2020355253A1
(en)
*
|
2019-09-27 |
2022-03-24 |
Agenus Inc. |
Heterodimeric proteins
|
AU2020353235A1
(en)
|
2019-09-28 |
2022-03-31 |
AskGene Pharma, Inc. |
Cytokine prodrugs and dual-prodrugs
|
MX2022003762A
(es)
|
2019-09-29 |
2022-06-24 |
Jacobio Pharmaceuticals Co Ltd |
Molécula de unión específica para el factor inhibidor de la leucemia (lif) y uso de la misma.
|
EP4055046A1
(en)
|
2019-11-06 |
2022-09-14 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
EP4057980A1
(en)
|
2019-11-15 |
2022-09-21 |
F. Hoffmann-La Roche AG |
Prevention of visible particle formation in aqueous protein solutions
|
KR20220113790A
(ko)
|
2019-12-13 |
2022-08-16 |
제넨테크, 인크. |
항-ly6g6d 항체 및 사용 방법
|
KR20220113791A
(ko)
|
2019-12-18 |
2022-08-16 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ccl2 항체
|
AU2020406085A1
(en)
|
2019-12-18 |
2022-05-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to HLA-A2/MAGE-A4
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
PE20221186A1
(es)
|
2019-12-23 |
2022-08-05 |
Genentech Inc |
Anticuerpos especificos de apolipoproteina l1 y metodos de uso
|
US20230058982A1
(en)
|
2019-12-27 |
2023-02-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody and use thereof
|
WO2021136772A1
(en)
|
2020-01-02 |
2021-07-08 |
F. Hoffmann-La Roche Ag |
Method for determining the amount of a therapeutic antibody in the brain
|
CA3165927A1
(en)
|
2020-01-11 |
2021-07-15 |
AskGene Pharma, Inc. |
Novel masked cytokines and methods of use thereof
|
EP4090666A1
(en)
|
2020-01-15 |
2022-11-23 |
F. Hoffmann-La Roche AG |
Methods to decrease impurities from recombinant protein manufacturing processes
|
IL294453A
(en)
|
2020-01-16 |
2022-09-01 |
Genmab As |
Formulations of cd38 antibodies and uses thereof
|
JP2023513003A
(ja)
|
2020-01-29 |
2023-03-30 |
インヒブルクス インコーポレイテッド |
Cd28シングルドメイン抗体ならびにその多価および多重特異性の構築物
|
GB202001447D0
(en)
|
2020-02-03 |
2020-03-18 |
Ucb Biopharma Sprl |
Antibodies
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
WO2021173844A1
(en)
|
2020-02-26 |
2021-09-02 |
Biograph 55, Inc. |
C19 c38 bispecific antibodies
|
IL296256A
(en)
|
2020-03-13 |
2022-11-01 |
Genentech Inc |
Antibodies against interleukin-33 and uses thereof
|
AR121599A1
(es)
|
2020-03-18 |
2022-06-22 |
Genmab As |
Anticuerpos
|
WO2021195464A2
(en)
|
2020-03-26 |
2021-09-30 |
Genentech, Inc. |
Modified mammalian cells
|
JP7285495B2
(ja)
|
2020-03-30 |
2023-06-02 |
国立大学法人三重大学 |
二重特異的抗体
|
CA3173519A1
(en)
|
2020-03-31 |
2021-10-07 |
Vishnu Priyanka Reddy CHICHILI |
Method for producing multispecific antigen-binding molecules
|
CN115485028A
(zh)
|
2020-04-15 |
2022-12-16 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
MX2022013173A
(es)
|
2020-04-24 |
2022-11-30 |
Hoffmann La Roche |
Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados.
|
US20230203161A1
(en)
|
2020-04-29 |
2023-06-29 |
Teneobio, Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
EP4142722A1
(en)
|
2020-04-30 |
2023-03-08 |
Bristol-Myers Squibb Company |
Methods of treating cytokine-related adverse events
|
MX2022013797A
(es)
|
2020-05-08 |
2022-11-30 |
Genmab As |
Anticuerpos biespecificos contra cd3 y cd20.
|
JP2023525032A
(ja)
|
2020-05-08 |
2023-06-14 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
T細胞阻害タンパク質を伴うおよび伴わない、aprilおよびbaff阻害免疫調節タンパク質、ならびにその使用方法
|
JP2023527690A
(ja)
|
2020-05-11 |
2023-06-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
改変pbmcと免疫抱合体との併用療法
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
EP4149421A1
(en)
|
2020-05-15 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Prevention of visible particle formation in parenteral protein solutions
|
WO2021233853A1
(en)
|
2020-05-19 |
2021-11-25 |
F. Hoffmann-La Roche Ag |
The use of chelators for the prevention of visible particle formation in parenteral protein solutions
|
EP4159859A1
(en)
|
2020-05-27 |
2023-04-05 |
Arialys Therapeutics, Inc. |
Anti-human nr1 antibody derivative
|
CN115697489A
(zh)
|
2020-06-08 |
2023-02-03 |
豪夫迈·罗氏有限公司 |
抗hbv抗体及其使用方法
|
MX2022015204A
(es)
|
2020-06-19 |
2023-01-05 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3.
|
CN115916825A
(zh)
|
2020-06-19 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
与cd3和cd19结合的抗体
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
BR112022025809A2
(pt)
|
2020-06-19 |
2023-01-10 |
Hoffmann La Roche |
Anticorpos, polinucleotídeo isolado, célula hospedeira, método para produzir um anticorpo, uso do anticorpo, método para tratar uma doença e invenção
|
BR112022025250A2
(pt)
|
2020-06-19 |
2022-12-27 |
Hoffmann La Roche |
Moléculas, um ou mais polinucleotídeos, um ou mais vetores, célula hospedeira, métodos para produzir uma molécula e induzir a lise de uma célula, composição farmacêutica, uso da molécula, métodos de tratamento de uma doença e invenção
|
IL299161A
(en)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
Cell lines resistant to apoptosis
|
EP4171614A1
(en)
|
2020-06-29 |
2023-05-03 |
Resolve Therapeutics, LLC |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
CN116133689A
(zh)
|
2020-07-07 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
作为治疗性蛋白质制剂的稳定剂的替代表面活性剂
|
AU2021303508A1
(en)
|
2020-07-10 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Antibodies which bind to cancer cells and target radionuclides to said cells
|
WO2022016037A1
(en)
|
2020-07-17 |
2022-01-20 |
Genentech, Inc. |
Anti-notch2 antibodies and methods of use
|
TW202216215A
(zh)
|
2020-07-21 |
2022-05-01 |
美商建南德克公司 |
Brm降解之抗體結合化學誘導物及其方法
|
EP4185388A1
(en)
|
2020-07-23 |
2023-05-31 |
Genmab B.V. |
A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
AU2021317974A1
(en)
|
2020-07-31 |
2023-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical Composition comprising Cell Expressing Chimeric Receptor
|
EP4188960A1
(en)
*
|
2020-08-03 |
2023-06-07 |
Janssen Biotech, Inc. |
Materials and methods for multidirectional biotransportation in virotherapeutics
|
JP2023536340A
(ja)
|
2020-08-06 |
2023-08-24 |
ビオンテック・ソシエタス・エウロパエア |
コロナウイルスsタンパク質のための結合剤
|
IL300666A
(en)
|
2020-08-19 |
2023-04-01 |
Xencor Inc |
ANTI–CD28 COMPOSITIONS
|
CN116648507A
(zh)
|
2020-08-28 |
2023-08-25 |
基因泰克公司 |
宿主细胞蛋白的CRISPR/Cas9多重敲除
|
WO2022044248A1
(ja)
|
2020-08-28 |
2022-03-03 |
中外製薬株式会社 |
ヘテロ二量体Fcポリペプチド
|
IL301085A
(en)
|
2020-09-10 |
2023-05-01 |
Genmab As |
A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
|
BR112023004351A2
(pt)
|
2020-09-10 |
2023-04-04 |
Genmab As |
Método para tratar linfoma folicular em um sujeito humano
|
KR20230066581A
(ko)
|
2020-09-10 |
2023-05-16 |
젠맵 에이/에스 |
미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
|
CA3190349A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
|
CA3189883A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
IL301100A
(en)
|
2020-09-10 |
2023-05-01 |
Genmab As |
A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
|
AU2021342566A1
(en)
|
2020-09-21 |
2023-03-02 |
Genentech, Inc. |
Purification of multispecific antibodies
|
JP2023542228A
(ja)
|
2020-09-24 |
2023-10-05 |
エフ. ホフマン-ラ ロシュ アーゲー |
遺伝子ノックアウトを有する哺乳動物細胞株
|
CA3193914A1
(en)
|
2020-10-02 |
2022-04-07 |
Louise KOOPMAN |
Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
|
IL301547A
(en)
|
2020-10-05 |
2023-05-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
TW202233671A
(zh)
|
2020-10-20 |
2022-09-01 |
美商建南德克公司 |
Peg結合抗mertk抗體及其使用方法
|
KR20230107305A
(ko)
|
2020-11-10 |
2023-07-14 |
상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 |
클라우딘 18a2 및 cd3에 대한 이중특이성 항체 및 이중특이성 항체의 용도
|
KR20230108288A
(ko)
|
2020-11-16 |
2023-07-18 |
아스텔라스세이야쿠 가부시키가이샤 |
항tspan8-항cd3 이중 특이성 항체 및 항tspan8 항체
|
CR20230253A
(es)
|
2020-11-16 |
2023-07-26 |
Hoffmann La Roche |
Glucoformas de fab ricas en manosa
|
MX2023006650A
(es)
|
2020-12-07 |
2023-06-21 |
UCB Biopharma SRL |
Anticuerpos multiespecificos y combinaciones de anticuerpos.
|
WO2022122652A1
(en)
|
2020-12-07 |
2022-06-16 |
UCB Biopharma SRL |
Antibodies against interleukin-22
|
CR20230263A
(es)
|
2020-12-17 |
2023-08-21 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos
|
CN116601175A
(zh)
|
2020-12-18 |
2023-08-15 |
豪夫迈·罗氏有限公司 |
用于靶向疗法的前体蛋白和试剂盒
|
CN116670282A
(zh)
|
2020-12-22 |
2023-08-29 |
豪夫迈·罗氏有限公司 |
靶向xbp1的寡核苷酸
|
EP4274658A1
(en)
|
2021-01-06 |
2023-11-15 |
F. Hoffmann-La Roche AG |
Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
KR20230131204A
(ko)
|
2021-01-12 |
2023-09-12 |
에프. 호프만-라 로슈 아게 |
암 세포에 결합하여 방사성핵종을 상기 세포에 표적화하는분할 항체
|
JP2024503654A
(ja)
|
2021-01-13 |
2024-01-26 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
併用療法
|
EP4277707A1
(en)
|
2021-01-14 |
2023-11-22 |
Askgene Pharma, Inc. |
Interferon prodrugs and methods of making and using the same
|
WO2022165443A1
(en)
|
2021-02-01 |
2022-08-04 |
AskGene Pharma, Inc. |
Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide
|
JP2024509695A
(ja)
|
2021-02-03 |
2024-03-05 |
ジェネンテック, インコーポレイテッド |
多重特異性結合タンパク質分解プラットフォームおよび使用方法
|
WO2022178103A1
(en)
|
2021-02-17 |
2022-08-25 |
AskGene Pharma, Inc. |
Il-2 receptor beta subunit mutants
|
JP2024512240A
(ja)
|
2021-02-18 |
2024-03-19 |
エフ. ホフマン-ラ ロシュ アーゲー |
複雑な多段階の抗体相互作用を解明するための方法
|
CN117157319A
(zh)
|
2021-03-09 |
2023-12-01 |
Xencor股份有限公司 |
结合cd3和cldn6的异二聚抗体
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Cd3及びgpc3に結合するヘテロ二量体抗体
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック, インコーポレイテッド |
抗klk7抗体、抗klk5抗体、多重特異性抗klk5/klk7抗体、及び使用方法
|
CA3210971A1
(en)
|
2021-03-12 |
2022-09-15 |
Bart-Jan DE KREUK |
Non-activating antibody variants
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
CN116897159A
(zh)
|
2021-03-31 |
2023-10-17 |
江苏恒瑞医药股份有限公司 |
截短的taci多肽及其融合蛋白和用途
|
IL307236A
(en)
|
2021-03-31 |
2023-11-01 |
Hoffmann La Roche |
Purification of antibodies by mixed-mode chromatography
|
EP4320444A1
(en)
|
2021-04-09 |
2024-02-14 |
F. Hoffmann-La Roche AG |
Process for selecting cell clones expressing a heterologous polypeptide
|
WO2022219076A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve the anti-tumoral activity of macrophages
|
WO2022219080A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
EP4326855A1
(en)
|
2021-04-19 |
2024-02-28 |
Genentech, Inc. |
Modified mammalian cells
|
TW202243689A
(zh)
|
2021-04-30 |
2022-11-16 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體及抗cd78b抗體藥物結合物的組合治療之給藥
|
AU2021443863A1
(en)
|
2021-04-30 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
IL308100A
(en)
|
2021-05-03 |
2023-12-01 |
UCB Biopharma SRL |
Antibodies
|
IL308336A
(en)
|
2021-05-07 |
2024-01-01 |
Alpine Immune Sciences Inc |
Methods of dosing and treatment with TACI-FC modulatory fusion protein
|
CA3214582A1
(en)
|
2021-05-07 |
2022-11-10 |
Martin SAHLIN |
Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3
|
JP2024518081A
(ja)
|
2021-05-12 |
2024-04-24 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
Ranklとngfに特異的に結合する抗原結合分子およびその医薬用途
|
WO2022237882A1
(zh)
|
2021-05-14 |
2022-11-17 |
江苏恒瑞医药股份有限公司 |
一种抗原结合分子
|
JP2024521107A
(ja)
|
2021-05-21 |
2024-05-28 |
ジェネンテック, インコーポレイテッド |
目的の組換え産物を産生するための修飾細胞
|
EP4355786A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
|
WO2022266221A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Monovalent anti-mertk antibodies and methods of use thereof
|
EP4355775A1
(en)
|
2021-06-18 |
2024-04-24 |
F. Hoffmann-La Roche AG |
Bispecific anti-ccl2 antibodies
|
EP4359435A1
(en)
|
2021-06-21 |
2024-05-01 |
Genmab A/S |
Combination dosage regime of cd137 and pd-l1 binding agents
|
TW202306999A
(zh)
|
2021-06-24 |
2023-02-16 |
美商艾瑞斯卡公司 |
抗egfr抗體及其用途
|
TW202311291A
(zh)
|
2021-06-25 |
2023-03-16 |
日商中外製藥股份有限公司 |
抗ctla-4抗體的用途
|
IL309115A
(en)
|
2021-06-25 |
2024-02-01 |
Chugai Pharmaceutical Co Ltd |
Anti-CTLA-4 antibodies
|
WO2023279092A2
(en)
|
2021-07-02 |
2023-01-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
US20230197278A1
(en)
|
2021-07-13 |
2023-06-22 |
Genentech, Inc. |
Multi-variate model for predicting cytokine release syndrome
|
EP4372001A1
(en)
|
2021-07-14 |
2024-05-22 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereof
|
TW202309097A
(zh)
|
2021-07-14 |
2023-03-01 |
美商建南德克公司 |
抗c-c模體趨化因子受體8(ccr8)抗體及其使用方法
|
EP4373859A1
(en)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimeric fc domain antibodies
|
CA3227537A1
(en)
|
2021-07-27 |
2023-02-02 |
Morphosys Ag |
Combinations of antigen binding molecules
|
CN117715936A
(zh)
|
2021-07-28 |
2024-03-15 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的方法和组合物
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
GB202111905D0
(en)
|
2021-08-19 |
2021-10-06 |
UCB Biopharma SRL |
Antibodies
|
AR127743A1
(es)
|
2021-09-06 |
2024-02-28 |
Genmab Bv |
Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
|
KR20240052854A
(ko)
|
2021-09-08 |
2024-04-23 |
조인트 스탁 컴퍼니 "바이오케드" |
Mhc 단백질 기반 이종 이량체를 포함하는 이중 특이적 항체
|
WO2023046071A1
(zh)
|
2021-09-23 |
2023-03-30 |
江苏恒瑞医药股份有限公司 |
抗klb抗体及用途
|
JPWO2023053282A1
(es)
|
2021-09-29 |
2023-04-06 |
|
|
CN117916273A
(zh)
|
2021-09-30 |
2024-04-19 |
江苏恒瑞医药股份有限公司 |
抗il23抗体融合蛋白及用途
|
US20230190806A1
(en)
|
2021-10-06 |
2023-06-22 |
Immatics Biotechnologies Gmbh |
Methods of treating metastatic lesions and compositions thereof
|
KR20240082388A
(ko)
|
2021-10-08 |
2024-06-10 |
추가이 세이야쿠 가부시키가이샤 |
프리필드 시린지 제제의 조제 방법
|
TW202330610A
(zh)
|
2021-10-08 |
2023-08-01 |
丹麥商珍美寶股份有限公司 |
結合至cd30及cd3之抗體
|
AU2022362681A1
(en)
|
2021-10-14 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
CN118139648A
(zh)
|
2021-10-14 |
2024-06-04 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的替代的PD1-IL7v免疫缀合物
|
WO2023081925A1
(en)
|
2021-11-08 |
2023-05-11 |
Immatics Biotechnologies Gmbh |
Adoptive cell therapy combination treatment and compositions thereof
|
WO2023094282A1
(en)
|
2021-11-25 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Quantification of low amounts of antibody sideproducts
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
WO2023114658A1
(en)
|
2021-12-13 |
2023-06-22 |
Kenjockety Biotechnology, Inc. |
Anti-abcb1 antibodies
|
WO2023117325A1
(en)
|
2021-12-21 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Method for the determination of hydrolytic activity
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
WO2023144306A1
(en)
|
2022-01-28 |
2023-08-03 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
US20230241211A1
(en)
|
2022-01-28 |
2023-08-03 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
WO2023159220A1
(en)
|
2022-02-18 |
2023-08-24 |
Kenjockety Biotechnology, Inc. |
Anti-cd47 antibodies
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
WO2023175064A1
(en)
|
2022-03-17 |
2023-09-21 |
Astrazeneca Ab |
Methods for purifying bispecific antibodies
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202404637A
(zh)
|
2022-04-13 |
2024-02-01 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體之醫藥組成物及使用方法
|
WO2023198839A2
(en)
|
2022-04-13 |
2023-10-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
TWI833641B
(zh)
|
2022-05-02 |
2024-02-21 |
丹麥商諾佛 儂迪克股份有限公司 |
適於高濃度組成物及皮下投藥之新穎抗angptl3抗體
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023219120A1
(ja)
*
|
2022-05-12 |
2023-11-16 |
アステラス製薬株式会社 |
抗cd37-抗cd3二重特異性抗体
|
TW202409090A
(zh)
|
2022-05-12 |
2024-03-01 |
丹麥商珍美寶股份有限公司 |
在組合療法中能夠結合到cd27之結合劑
|
WO2023218046A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
WO2023218431A1
(en)
|
2022-05-13 |
2023-11-16 |
BioNTech SE |
Rna compositions targeting hiv
|
WO2023232961A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
TW202405020A
(zh)
|
2022-07-29 |
2024-02-01 |
美商阿列克特有限責任公司 |
轉鐵蛋白受體抗原結合域及其用途
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
WO2024077018A2
(en)
|
2022-10-04 |
2024-04-11 |
Alpine Immune Sciences, Inc. |
Methods and uses of taci-fc fusion immunomodulatory protein
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
WO2024079009A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and proteasome inhibitors
|
WO2024079015A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and imids
|
WO2024079010A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and cd38 antibodies
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
WO2024081918A1
(en)
|
2022-10-14 |
2024-04-18 |
Talem Therapeutics Llc |
Anti-trkb/cd3 antibodies and uses thereof
|
WO2024088921A1
(en)
|
2022-10-24 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Predicting response to il-6 antagonists
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
WO2024094660A1
(en)
|
2022-10-31 |
2024-05-10 |
Genmab A/S |
Cd38 antibodies and uses thereof
|
WO2024094822A1
(en)
|
2022-11-02 |
2024-05-10 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20 for treating richter's syndrome
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
WO2024104933A1
(en)
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules
|
WO2024104988A1
(en)
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with activatable effector domain
|
WO2024110426A1
(en)
|
2022-11-23 |
2024-05-30 |
F. Hoffmann-La Roche Ag |
Method for increasing recombinant protein expression
|
WO2024110905A1
(en)
|
2022-11-24 |
2024-05-30 |
Beigene, Ltd. |
Anti-cea antibody drug conjugates and methods of use
|
WO2024119193A2
(en)
|
2022-12-02 |
2024-06-06 |
AskGene Pharma, Inc. |
Mutant il-2 polypeptides and il-2 prodrugs
|
WO2024129594A1
(en)
|
2022-12-12 |
2024-06-20 |
Genentech, Inc. |
Optimizing polypeptide sialic acid content
|